Peter Alping

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Jag är en Postdoktor vid Avdelningen för Klinisk Epidemiologi, Institutionen för Medicin, Solna. Min forskning är huvudsakligen fokuserad på multipel skleros.

Artiklar

Article: ANNALS OF NEUROLOGY. 2024;96(4):694-703
Hospital-Treated Infections and Risk of Disability Worsening in Multiple Sclerosis
Hu Y; Frisell T; Alping P; Song H; Pawitan Y; Fang F; Piehl F
Article: ANNALS OF NEUROLOGY. 2024;96(4):678-693
COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab
Piehl F; Alping P; Virtanen S; Englund S; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Mellergard J; Nilsson P; Olsson T; Salzer J; Svenningsson A; Frisell T
Article: ANNALS OF NEUROLOGY. 2024;95(6):1099-1111
Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study
Alping P; Neovius M; Piehl F; Frisell T
Article: MULTIPLE SCLEROSIS JOURNAL. 2023;29(6):731-740
Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
Fink K; Gorczyca A; Alping P; Englund S; Farmand S; Langer-Gould AM; Piehl F; McKay K; Frisell T; Razaz N
Article: NEUROLOGY. 2021;96(11):e1574-e1584
Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
Alping P; Burman J; Lycke J; Frisell T; Piehl F
Article: ANNALS OF NEUROLOGY. 2020;87(5):688-699
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
Alping P; Askling J; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
Article: JAMA NEUROLOGY. 2020;77(2):184-191
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
Luna G; Alping P; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
Article: EPIDEMIOLOGY. 2019;30(2):230-233
Validation of the Swedish Multiple Sclerosis Register Further Improving a Resource for Pharmacoepidemiologic Evaluations
Alping P; Piehl F; Langer-Gould A; Frisell T; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Kockum I; Lycke J; Nilsson P; Olsson T; Salzer J; Svenningsson A; Virtanen S; Vrethem M
Article: NEUROLOGY. 2016;87(20):2074-2081
Rituximab in multiple sclerosis A retrospective observational study on safety and efficacy
Salzer J; Svenningsson R; Alping P; Novakova L; Bjorck A; Fink K; Islam-Jakobsson P; Malmestrm C; Axelsson M; Vagberg M; Sundstrom P; Lycke J; Piehl F; Svenningsson A
Article: ANNALS OF NEUROLOGY. 2016;79(6):950-958
Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
Alping P; Frisell T; Novakova L; Islam-Jakobsson P; Salzer J; Bjorck A; Axelsson M; Malmestrom C; Fink K; Lycke J; Svenningsson A; Piehl F

Alla övriga publikationer

Review: BASIC AND CLINICAL PHARMACOLOGY AND TOXICOLOGY. 2023;133(5):550-564
Disease-modifying therapies in multiple sclerosis: A focused review of rituximab
Alping P
Thesis / dissertation: 2022
Pharmacoepidemiological studies of rituximab and other recent therapies in multiple sclerosis
Alping, Peter
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):106
Multiple sclerosis and risks for adverse perinatal and pregnancy outcomes: Results from a nationwide cohort study
Fink K; Gorczyca A; Alping P; Langer-Gould AM; Cnattingius S; Frisell T; Piehl F; Razaz N
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):634-635
Rituximab treatment prior to pregnancy in women with multiple sclerosis - perinatal outcomes in Swedish cohort
Gorczyca A; Alping P; Frisell T; Razaz N; Piehl F; Fink K
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):21-22
Effectiveness of initial MS treatments in the COMBAT-MS trial: injectables, dimethyl fumarate, natalizumab and rituximab
Alping P; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Olsson T; Salzer J; Svenningsson A; Vrethem M; Frisell T; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2020;26(3_SUPPL):352-353
Safety outcomes after treatment with alemtuzumab or autologous hematopoietic stem cell transplantation in multiple sclerosis patients
Alping P; Burman J; Lycke J; Frisell T; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2019;25:570-571
Rituximab does not increase the risk of malignancy or breast cancer in two large US and Swedish rituximab-treated multiple sclerosis cohorts
Langer-Gould A; Alping P; Smith J; Li B; Piehl F; Frisell T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2018;24:36
Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab.
Alping P; Piehl F; Frisell T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2018;24:146-147
Disease-modifying therapies for multiple sclerosis in association with pregnancy: a Swedish nation-wide cohort study
Gorczyca A; Alping P; Frisell T; Piehl F; Langer-Gould A; Fink K
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2017;23:714
Baseline characteristics from the COMBAT-MS study: Initial analyses suggest main driver for therapy choice is geographic location
Alping P; Burman J; Fink K; Gunnarsson M; Lycke J; Nilsson P; Salzer J; Vrethem M; Langer-Gould A; Svenningsson A; Frisell T; Piehl F
Letter: ANNALS OF NEUROLOGY. 2016;80(5):791-792
Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk Reply
Alping P; Frisell T; Svenningsson A; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2016;22:49
Rituximab in multiple sclerosis; data from the swedish MS registry.
Alping P; Svenningsson A; Salzer J; Burman J; Dahle C; Fink K; Hillert J; Lycke J; Landtblom A-M; Martin C; Nilsson P; Walentin F; Olsson T; Frisell T; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:574
Rituximab in multiple sclerosis, a long term safety and efficacy study
Islam-Jakobsson P; Alping P; Salzer J; Bjorck A; Fink K; Frisell T; Piehl F; Svenningsson A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:555
Superior efficacy and tolerability of rituximab as compared to fingolimod for MS patients switching from natalizumab due to positive JC virus serology
Alping P; Islam-Jakobsson P; Novakova L; Salzer J; Bjorck A; Axelsson M; Malmestrom C; Fink K; Frisell T; Lycke J; Svenningsson A; Piehl F

Anställningar

Postdoktor, Medicin, Solna, Karolinska Institutet, 2023-2025
AT-Läkare, Karolinska Universitetssjukhuset, 2021-2023
Doktorand, Klinisk neurovetenskap, Karolinska Institutet, 2016-2022
Läkare, Stockholms Läns Sjukvårdsområde (SLSO), 2020-2020

Examina och utbildning

Medicine Doktorsexamen, Pharmacoepidemiological studies of rituximab and other recent therapies in multiple sclerosis, Institutionen för klinisk neurovetenskap, Karolinska Institutet, 2022
Läkarexamen, Karolinska Institutet, 2017

Om mig

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI